Current Pharmaceutical Design

William A. Banks  
VAPSHCS/GRECC S-182
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108
USA

Back

Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders

Author(s): Luis M. Valor, Jose Viosca, Jose P. Lopez-Atalaya and Angel Barco

Affiliation: Instituto de Neurociencias (Universidad Miguel Hernandez – Consejo Superior de Investigaciones Cientificas), Av. Santiago Ramon y Cajal s/n. Sant Joan d’Alacant 03550, Alicante, Spain.

Abstract:

Neuropsychiatric pathologies, including neurodegenerative diseases and neurodevelopmental syndromes, are frequently associated with dysregulation of various essential cellular mechanisms, such as transcription, mitochondrial respiration and protein degradation. In these complex scenarios, it is difficult to pinpoint the specific molecular dysfunction that initiated the pathology or that led to the fatal cascade of events that ends with the death of the neuron. Among the possible original factors, epigenetic dysregulation has attracted special attention. This review focuses on two highly related epigenetic factors that are directly involved in a number of neurological disorders, the lysine acetyltransferases CREB-binding protein (CBP) and E1A-associated protein p300 (p300). We first comment on the role of chromatin acetylation and the enzymes that control it, particularly CBP and p300, in neuronal plasticity and cognition. Next, we describe the involvement of these proteins in intellectual disability and in different neurodegenerative diseases. Finally, we discuss the potential of ameliorative strategies targeting CBP/p300 for the treatment of these disorders.

Keywords: Histone acetylation, CBP, p300, Rubinstein-Taybi syndrome, Huntington’s disease, Alzheimer’s disease, HDACi, KATe, KATi.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

VOLUME: 19
ISSUE: 28
Page: [5051 - 5064]
Pages: 14
DOI: 10.2174/13816128113199990382